Observation And Evaluation Of The Effect Of RhGH In ISS Children With Diffrent Bone Ages Before Puberty

Objective: To observe the effect of recombinant human growth hormone(rh GH)on height,weight and bone age in children with idiopathic short stature(ISS)at different bone ages before puberty,and to explore the necessity of early detection and early treatment of idiopathic short stature.Methods: From December 2017 to February 2019,65 cases of idiopathic short stature were diagnosed in the outpatient clinic of Ningxia People's Hospital,which were divided into two groups according to different bone age(1 group <8 years old bone age,2 groups ?8 years old bone age).After one year of treatment with recombinant human growth hormone,the height,weight and bone age of all children were observed,and the growth rate of height and change of height SDS was observed in both groups,assess the difference in height growth rate after treatment with recombinant human growth hormone in different bone age groups and observe free triiodothyronine(FT3),free thyroxine(FT4),thyroid stimulating hormone(TSH),blood glucose levels.Results: The bone age of all children after treatment increased slightly after treatment,but it was not statistically significant compared with that before treatment(P >0.05).After treatment,the weight,height and growth rate were all increased,the difference was statistically significant(P <0.05).The growth rate of the two groups was significantly higher than that before treatment,after comparing the two groups,it was obvious that the growth rate of group 1 was slightly higher than that of group 2,but it did not reach statistical significance(P>0.05).Children with bone age less than 8years of age had significantly higher change of height SDS after treatment than children with bone age greater than 8 years of age,it has statistical significance(P>0.05).There were no abnormalities in free triiodothyronine(FT3),free thyroxine(FT4),thyrotropin(TSH)and blood glucose per 3 months of follow-up in the selected cases.During the course of treatment,have 5 children had lower extremity pain and have one that the child had patient had red skin at the injection site.Conclusion: Recombinant human growth hormone can promote bone growth in children with idiopathic short stature.The growth rate after treatment was significantly higher than that before treatment,and the growth rate of children with small bone age after treatment with recombinant human growth hormone was slightly higher than that of the group with large bone age.The change of height SDS improvement of small bone age group was more obvious than that of larger bone age group.The use of recombinant human growth hormone in children with idiopathic short stature has clinical value and the safety of medication is high.